IRadimed Corporation (IRMD) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	86.3M	83.8M	73.2M	65.6M	53.3M
Cost of Revenue	20.8M	19.5M	16.9M	15.4M	12.0M
Gross Profit	65.5M	64.3M	56.3M	50.2M	41.3M
Operating Expenses
R&D Expense	3.1M	3.0M	2.8M	2.9M	2.3M
SG&A Expense	34.9M	35.2M	31.6M	27.3M	23.4M
General & Admin Expense	17.3M	17.8M	15.9M	15.1M	10.7M
Selling & Marketing Expense	17.5M	17.4M	15.6M	12.1M	12.7M
Other Expenses	—	—	—	—	—
Total Operating Expenses	37.9M	38.2M	34.4M	30.1M	25.7M
Cost and Expenses	58.8M	57.7M	51.3M	45.5M	37.7M
Operating Income (EBIT)	27.6M	26.1M	22.0M	20.0M	15.6M
Non-Operating
Interest Income	—	—	2.2M	1.9M	581.9K
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	2.2M	1.9M	581.9K
Other Non-Op Income/Expense	2.2M	2.2M	2.3M	1.7M	553.1K
Non-Operating Income (excl Interest)	(1.7M)	(2.2M)	(2.3M)	(1.7M)	(553.1K)
EBT (Pre-Tax Income)	29.7M	28.4M	24.3M	21.7M	16.2M
Income Tax Expense	6.7M	5.9M	5.0M	4.5M	3.4M
Bottom Line
Net Income	23.1M	22.5M	19.2M	17.2M	12.8M
Earnings from Cont. Ops	23.1M	22.5M	19.2M	17.2M	12.8M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	23.1M	22.5M	19.2M	17.2M	12.8M
Per Share
Basic EPS	$1.82	$1.77	$1.52	$1.36	$1.02
Diluted EPS	$1.79	$1.75	$1.50	$1.35	$1.02
Revenue Per Share	$6.75	$6.59	$5.78	$5.20	$4.24
Shares
Basic Shares Outstanding	12.8M	12.7M	12.7M	12.6M	12.6M
Diluted Shares Outstanding	12.9M	12.9M	12.8M	12.7M	12.6M
Profitability Metrics
EBITDA	31.1M	30.7M	25.1M	22.5M	16.9M
D&A	1.9M	2.4M	817.7K	765.2K	670.7K
EBIT	29.2M	28.4M	24.3M	21.7M	16.2M

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026